U.K. - DART-AD Dementia AP Reduction Trial
		Enrolled residents of nursing or residential homes in four areas (2001-2004); followed patients to April 2006 All patients had been diagnosed with possible or probable Alzheimer’s and all had taken APs for ≥ 3 months (APs = risperidone, thioridazine, haloperidol, trifluoperazine, or chlorpromazine) Mean duration of drug use:     25 months